Diakonos Oncology Corporation

This study is testing whether adding a personalized immune cell therapy (DOC1021) to standard surgery, chemotherapy, and radiation can help adults newly diagnosed with a fast-growing brain tumor called glioblastoma live longer. Researchers will compare survival between two groups…

This clinical trial is testing a personalized immunotherapy called DOC1021 for patients with melanoma that has stopped responding to standard treatments. The therapy uses a patient's own immune cells, loaded with markers from their tumor, to train the immune system to attack the …